CompletedPhase 2NCT00002940
Hydroxyurea in Treating Patients With Epstein-Barr Virus-Associated Primary CNS Lymphoma and AIDS
Studying Epstein-Barr virus-associated malignant lymphoproliferative disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- St. Jude Children's Research Hospital
- Principal Investigator
- Karen S. Slobod, MDSt. Jude Children's Research Hospital
- Intervention
- hydroxyurea(drug)
- Eligibility
- All sexes
- Timeline
- 1996 – 2002
Study locations (2)
- Louisiana State University Health Sciences Center - Shreveport, Shreveport, Louisiana, United States
- Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002940 on ClinicalTrials.govOther trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07381738Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative DisordersFudan University
- RECRUITINGPHASE1, PHASE2NCT07450391EBV-AST Cell Injection for EBV-Associated Lymphoproliferative DisordersDaihong Liu
See all trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder →